Xu Y - Search Results

1

Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy.

Ye J, Hou B, Chen F, Zhang S, Xiong M, Li T, Xu Y, Xu Z, Yu H. Ye J, et al. Among authors: xu y, xu z. Acta Pharm Sin B. 2022 Jun;12(6):2695-2709. doi: 10.1016/j.apsb.2021.09.021. Epub 2021 Sep 25. Acta Pharm Sin B. 2022. PMID: 35755274 Free PMC article.

2

Allosteric Regulation of Hsp90α's Activity by Small Molecules Targeting the Middle Domain of the Chaperone.

Zhou C, Zhang C, Zhu H, Liu Z, Su H, Zhang X, Chen T, Zhong Y, Hu H, Xiong M, Zhou H, Xu Y, Zhang A, Zhang N. Zhou C, et al. Among authors: xu y. iScience. 2020 Feb 21;23(2):100857. doi: 10.1016/j.isci.2020.100857. Epub 2020 Jan 21. iScience. 2020. PMID: 32058968 Free PMC article.

3

Structural basis of ligand binding modes at the human formyl peptide receptor 2.

Chen T, Xiong M, Zong X, Ge Y, Zhang H, Wang M, Won Han G, Yi C, Ma L, Ye RD, Xu Y, Zhao Q, Wu B. Chen T, et al. Among authors: xu y. Nat Commun. 2020 Mar 5;11(1):1208. doi: 10.1038/s41467-020-15009-1. Nat Commun. 2020. PMID: 32139677 Free PMC article.

4

In Silico Screening-Based Discovery of Novel Inhibitors of Human Cyclic GMP-AMP Synthase: A Cross-Validation Study of Molecular Docking and Experimental Testing.

Zhao W, Xiong M, Yuan X, Li M, Sun H, Xu Y. Zhao W, et al. Among authors: xu y. J Chem Inf Model. 2020 Jun 22;60(6):3265-3276. doi: 10.1021/acs.jcim.0c00171. Epub 2020 Jun 9. J Chem Inf Model. 2020. PMID: 32459092

5

USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines.

Wang H, Meng Q, Ding Y, Xiong M, Zhu M, Yang Y, Su H, Gu L, Xu Y, Shi L, Zhou H, Zhang N. Wang H, et al. Among authors: xu y. FEBS J. 2021 Feb;288(4):1325-1342. doi: 10.1111/febs.15461. Epub 2020 Jul 20. FEBS J. 2021. PMID: 32578360 Free article.

6

What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.

Xiong M, Su H, Zhao W, Xie H, Shao Q, Xu Y. Xiong M, et al. Among authors: xu y. Med Res Rev. 2021 Jul;41(4):1965-1998. doi: 10.1002/med.21783. Epub 2021 Jan 18. Med Res Rev. 2021. PMID: 33460213 Free PMC article. Review.

7

In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.

Xiong M, Nie T, Shao Q, Li M, Su H, Xu Y. Xiong M, et al. Among authors: xu y. Eur J Med Chem. 2022 Mar 5;231:114130. doi: 10.1016/j.ejmech.2022.114130. Epub 2022 Jan 23. Eur J Med Chem. 2022. PMID: 35114541 Free PMC article.

8

Unraveling the catalytic mechanism of SARS-CoV-2 papain-like protease with allosteric modulation of C270 mutation using multiscale computational approaches.

Shao Q, Xiong M, Li J, Hu H, Su H, Xu Y. Shao Q, et al. Among authors: xu y. Chem Sci. 2023 Apr 11;14(18):4681-4696. doi: 10.1039/d3sc00166k. eCollection 2023 May 10. Chem Sci. 2023. PMID: 37181765 Free PMC article.

9

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease.

Wang Q, Chen G, He J, Li J, Xiong M, Su H, Li M, Hu H, Xu Y. Wang Q, et al. Among authors: xu y. Int J Mol Sci. 2023 May 11;24(10):8633. doi: 10.3390/ijms24108633. Int J Mol Sci. 2023. PMID: 37239980 Free PMC article.

10

Discovery of novel cGAS inhibitors based on natural flavonoids.

Li J, Xiong M, Liu J, Zhang F, Li M, Zhao W, Xu Y. Li J, et al. Among authors: xu y. Bioorg Chem. 2023 Nov;140:106802. doi: 10.1016/j.bioorg.2023.106802. Epub 2023 Aug 22. Bioorg Chem. 2023. PMID: 37666112

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73,573 results

Search Page

Filters